The shares of MoneyGram may bounce back to better days as the legal team representing Ripple reportedly had a great showing in the first court hearing.
Owing to the expectations of strong economic recovery, the bond yields jumped 1.35% on Monday, with a total surge of 27 basis points so far in February. While stocks remained under pressure, the long-term effect of growing economic activity could be positive for Wall Street.
The trio of Nvidia, Mattel and Domino’s Pizza are receiving a special focus for the week.
Currently, there are close to 1,000 pending similar cases against Uber which had been stayed until this case was completed.
Robinhood CEO was met by most of the fury owing to the fact that the app denied retail investors a chance to trade securities amid heightened volatility.
Shares for Virgin Galactic have been fluctuating in the past few weeks which is linked to on-going speculation and rumours about a test launch.
FAANG stocks are expected to continue with the 2020 rally as their demand prevails on the ground.
Barclays linked the rise in its full-year income to a solid performance in its corporate and investment sectors which overshadowed a low performance from its retail business.
Shopify has thrived significantly during the pandemic, but the possibility of a coronavirus crisis subsiding in the coming quarters leaves the business with some degree of uncertainty.
The reported growth of the Coinbase shares is a reflection of the blossoming business of cryptocurrency trading.
Iron-ore accounted for 90% of Rio Tinto’s earnings, underlying its pedigree as it operates one of the world’s biggest iron-ore export hubs.
With the deal announced a month ago, Amazon stock investors are closely monitoring to see if the acquisition was already factored into.
Wedbush noted the probability of less than 5% that public companies will adopt BTC over the coming 12 to 18 months.
The Wedbush analyst has positively rated Microsoft shares for the past 2 years. During this period, the tech company has had a one-year high of $245.92 and a one-year low of $132.52.
Notably, the World Health Organization has approved two different versions of the AstraZeneca vaccine that were found out to be approximately 63% effective.